548 filings
Page 7 of 28
8-K
3ds9jtdfssgn3 sxk
25 Apr 18
Other Events
12:00am
8-K
3sqe83g2g1f 30j
4 Apr 18
Abiomed Announces European Approval (CE Marking) for Impella 5.5™ and First Patient Treated at University Heart Center Hamburg
12:00am
8-K
ckqtw185s
2 Apr 18
Abiomed to Appoint New Chief Financial Officer Todd A. Trapp
12:00am
8-K
4voxft5i
8 Mar 18
Other Events
12:00am
8-K
wj9iitsm92hpc42p6vfl
14 Feb 18
Abiomed Receives Approval for Expanded FDA Indication for High Risk Percutaneous Coronary Intervention (PCI) Procedures
12:00am
8-K
c5scyy24d9rgrzinh5p1
14 Feb 18
Abiomed Receives Approval for Expanded FDA Indication for Cardiomyopathy with Cardiogenic Shock
12:00am
8-K
tupoia1
1 Feb 18
Abiomed Announces Q3 Fy 2018 Record Revenue of $154 Million, Up 34% Over Prior Year
12:00am
8-K
nlhfl16
8 Jan 18
Abiomed Announces Preliminary Q3 Fy 2018 Revenue of $154 Million, Up 34% Over Prior Year
12:00am
8-K
4rmyx5mbtmo
26 Oct 17
Results of Operations and Financial Condition
12:00am
8-K
lys5ueg 4oh1x
21 Sep 17
Abiomed Receives FDA PMA Approval for Impella RP® for Right Heart Failure
12:00am
8-K
e1z893
12 Sep 17
Entry into a Material Definitive Agreement
12:00am
8-K
q1rgw3uuxp2
28 Aug 17
Abiomed Announces Resignation of Chief Financial Officer and Welcomes Back Former
12:00am
8-K
xvfajocsm1xb5
15 Aug 17
Submission of Matters to a Vote of Security Holders
12:00am
8-K
45r74
3 Aug 17
Other Events
12:00am
8-K
p8okik
27 Jul 17
Abiomed Announces Q1 Fy 2018 Revenue of $132.5 Million, Up 29% Over Prior Year
12:00am
DEFA14A
b2ccsg sz7rafuujc
23 Jun 17
Additional proxy soliciting materials
12:00am